Core Insights - Adia Nutrition Inc. is preparing to file its Form 10 registration statement with the SEC, marking a significant transition from OTC reporting to full SEC compliance, which enhances transparency and credibility [1][2][3] - The filing is expected to be submitted by the end of November 2025, with a 60-day SEC review period, aiming for full effectiveness by late January 2026 [2] - This move is crucial for meeting Nasdaq listing requirements, potentially attracting institutional and accredited investors [2][3] Company Overview - Adia Nutrition Inc. operates in two main divisions: a supplement division offering premium organic supplements and a medical division focused on advanced stem cell therapies [5] - The company aims to empower individuals through innovative healthcare solutions, particularly in regenerative medicine and clinical services [5] Strategic Partnerships - The company is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its regenerative therapies [4]